Epigenetic Remodeling in Thyroid Cancer: New Dimensions of Targeted Therapy Through lncRNA Modulation

Area of Science:

• Molecular Oncology
• Epigenetics
• Cancer Biology

Background:

• Thyroid carcinomas exhibit significant phenotypic heterogeneity.
• Genetic, epigenetic, and non-genetic factors contribute to this heterogeneity.
• Understanding these factors is crucial for developing effective treatments.

Purpose of the Study:

• To evaluate the impact of various anticancer agents, natural compounds, and epigenetic modulators on thyroid cancer cells.
• To assess effects on long noncoding RNA expression, methylation regulators, and cellular functions.
• To explore synergistic effects of combined treatments in the K1 human thyroid cancer cell line.

Main Methods:

• K1 cells were treated with single and combined agents including Carboplatin, Doxorubicin, Paclitaxel, Avastin, Quercetin, suberoylanilide hydroxamic acid, and 5-Azacytidine.
• Evaluated drug-induced cytotoxicity, apoptosis, cell cycle distribution, cytokine release, gene expression, and global DNA methylation.
• Analyzed changes in specific genes (DNMT1, DNMT3B, EZH2) and long noncoding RNAs (lncRNAs).

Main Results:

• Single and combined treatments demonstrated anti-tumor activity by modulating cell cycle and apoptosis.
• Gene expression analysis revealed treatment-specific regulation of target genes and lncRNAs.
• All treatments increased global DNA methylation; specific combinations upregulated DNMT1/DNMT3B and downregulated EZH2.

Conclusions:

• Coordinated epigenetic changes were observed, highlighting therapeutic potential.
• Combining epigenetic modulators with chemotherapy may offer a strategy to overcome treatment resistance.
• This approach could potentially improve outcomes for thyroid cancer patients.